GlassScriptPhysician profile
Lawrence Zeidman
NPI 1467608943
$31,425.36
in general payments reported to CMS, 2019-2025
18 companies · $7,051 in 2025
The $7,051 reported for 2025 was more than what 86% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,191 · 2020: $1,200 · 2021: $4,857 · 2022: $5,095 · 2023: $2,235 · 2024: $8,797 · 2025: $7,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Travel and Lodging: $2,550 · Food and Beverage: $1,047 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $621 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,765.00 |
| Travel and Lodging | $2,550.36 |
| Food and Beverage | $1,047.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $620.90 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $8,109.70 | 2020-2022 | |
| Pfizer INC. | $6,234.63 | 2021-2025 | |
| Argenx US, INC. | $6,181.76 | 2024 | Vyvgart |
| Janssen Scientific Affairs, LLC | $4,565.83 | 2023-2024 | |
| Akcea Therapeutics, INC. | $2,191.04 | 2019 | |
| Octapharma USA, INC. | $2,089.84 | 2023-2025 | Panzyga |
| Takeda Pharmaceuticals U.S.A., INC. | $1,500.00 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $117.35 | 2021-2022 | |
| Genzyme Corporation | $115.02 | 2024 | |
| Janssen Biotech, INC. | $99.00 | 2025 | |
| Abbvie INC. | $59.17 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $37.18 | 2022 | |
| Novartis Pharmaceuticals Corporation | $30.81 | 2025 | |
| Tanabe Pharma America, INC. | $28.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.05 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $23.90 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.08 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Zeidman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.